CR20230476A - Proteínas de unión a pd-1 y tigit biespecíficas y usos de estas - Google Patents

Proteínas de unión a pd-1 y tigit biespecíficas y usos de estas

Info

Publication number
CR20230476A
CR20230476A CR20230476A CR20230476A CR20230476A CR 20230476 A CR20230476 A CR 20230476A CR 20230476 A CR20230476 A CR 20230476A CR 20230476 A CR20230476 A CR 20230476A CR 20230476 A CR20230476 A CR 20230476A
Authority
CR
Costa Rica
Prior art keywords
binding proteins
bispecific
tigit binding
disclosure
uses therof
Prior art date
Application number
CR20230476A
Other languages
English (en)
Inventor
Deepali Malhotra
Eleanor Clancy-Thompson
Stacy Pryts
Yariv Mazor
Yue Wang
Michael Overstreet
Karin Lee
Gordon Moody
Scott Hammond
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of CR20230476A publication Critical patent/CR20230476A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción se relaciona con proteínas de unión, que incluyen anticuerpos, que se unen a muerte programada 1 (“PD-1”) y al inmunorreceptor de células T con dominios Ig e ITIM (“TIGIT”). La descripción también proporciona composiciones que comprenden tales proteínas de unión y moléculas de ácido nucleico que codifican tales proteínas de unión. La descripción también se relaciona con métodos para tratar un trastorno o afección usando tales proteínas de unión.
CR20230476A 2021-04-30 2022-04-29 Proteínas de unión a pd-1 y tigit biespecíficas y usos de estas CR20230476A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182156P 2021-04-30 2021-04-30
PCT/IB2022/053997 WO2022229919A2 (en) 2021-04-30 2022-04-29 Bispecific pd-1 and tigit binding proteins and uses therof

Publications (1)

Publication Number Publication Date
CR20230476A true CR20230476A (es) 2024-01-30

Family

ID=83846748

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230476A CR20230476A (es) 2021-04-30 2022-04-29 Proteínas de unión a pd-1 y tigit biespecíficas y usos de estas

Country Status (17)

Country Link
US (2) US11939382B2 (es)
EP (1) EP4329803A4 (es)
JP (1) JP2024517558A (es)
KR (1) KR20240004300A (es)
CN (1) CN117202933A (es)
AR (1) AR125488A1 (es)
AU (1) AU2022265633A1 (es)
BR (1) BR112023020193A2 (es)
CA (1) CA3212025A1 (es)
CL (1) CL2023002928A1 (es)
CO (1) CO2023013140A2 (es)
CR (1) CR20230476A (es)
EC (1) ECSP23074489A (es)
IL (1) IL307284A (es)
MX (1) MX2023011610A (es)
TW (1) TW202309086A (es)
WO (1) WO2022229919A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20230476A (es) 2021-04-30 2024-01-30 Medimmune Llc Proteínas de unión a pd-1 y tigit biespecíficas y usos de estas
WO2023215719A1 (en) * 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
JP2026506893A (ja) 2023-02-23 2026-02-27 イムチェック セラピューティクス エスエーエス Ｂｔｎ３ａ活性化抗体と免役チェックポイント阻害剤の併用
WO2024216007A2 (en) * 2023-04-13 2024-10-17 Medimmune, Llc Pd-1/tigit binding proteins for cancer treatment
WO2026094002A1 (en) 2024-11-04 2026-05-07 Astrazeneca Ab Bispecific t-cell engager molecule combinations for use in treatment of claudin18.2 expressing solid tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
SG11201901077RA (en) * 2016-08-17 2019-03-28 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
TW201930358A (zh) * 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
KR102839330B1 (ko) * 2018-01-15 2025-07-30 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
TW202021618A (zh) * 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
TWI760751B (zh) * 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
CR20230476A (es) 2021-04-30 2024-01-30 Medimmune Llc Proteínas de unión a pd-1 y tigit biespecíficas y usos de estas

Also Published As

Publication number Publication date
CN117202933A (zh) 2023-12-08
US20240287183A1 (en) 2024-08-29
AU2022265633A1 (en) 2023-09-28
JP2024517558A (ja) 2024-04-23
US20220411509A1 (en) 2022-12-29
AR125488A1 (es) 2023-07-19
ECSP23074489A (es) 2023-12-29
MX2023011610A (es) 2023-10-11
US12570744B2 (en) 2026-03-10
IL307284A (en) 2023-11-01
WO2022229919A2 (en) 2022-11-03
KR20240004300A (ko) 2024-01-11
CO2023013140A2 (es) 2023-10-19
TW202309086A (zh) 2023-03-01
WO2022229919A3 (en) 2023-01-05
EP4329803A2 (en) 2024-03-06
CA3212025A1 (en) 2022-11-03
AU2022265633A9 (en) 2024-01-25
BR112023020193A2 (pt) 2023-11-14
US11939382B2 (en) 2024-03-26
EP4329803A4 (en) 2025-04-16
CL2023002928A1 (es) 2024-04-12

Similar Documents

Publication Publication Date Title
MX2023011610A (es) Proteinas de union a la proteina de muerte programada 1 (pd-1) y al inmunorreceptor de celulas con dominios de inmunoglobulina y motivos de inhibicion de inmunorreceptores a base de tirosina (tigit) biespecificas y usos de las mismas.
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
DE602005022830D1 (de) Weniger immunogene bindungsmoleküle
NZ790656A (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
NZ750132A (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
WO2020041541A3 (en) Anti-tigit antibodies
UA83791C2 (ru) Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
MX2021013850A (es) Anticuerpo contra tigit y uso del mismo.
PL392809A1 (pl) Przeciwciało monoklonalne przeciwko CD40 i jego część wiążąca antygen, zawierająca go kompozycja i jego zastosowanie, oraz linia komórkowa, cząsteczka kwasu nukleinowego, wektor komórka gospodarza i sposób wytwarzania
TNSN06216A1 (en) Antibodies to MAdCAM
EA200701443A1 (ru) Синтетические домены иммуноглобулина, обладающие свойствами связывания и сконструированные в участках молекулы, отличных от гипервариабельных участков
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
MX2022006709A (es) Anticuerpos antiidiotípicos para dominios de unión dirigidos a bcma y métodos y composiciones relacionadas.
MX2022001068A (es) Anticuerpo anti-il17a humanizado y uso del mismo.
PH12021550244A1 (en) Anti-btla antibody
MX2023014666A (es) Agentes aglutinantes biespecificos que se unen a cldn18.2 y cd3.
MX2021013441A (es) Molecula de union a antigenos, composicion farmaceutica y metodo.
Blanc et al. A one‐step exclusion‐binding procedure for the purification of functional heavy‐chain and mammalian‐type γ‐globulins from camelid sera
BR112023020365A2 (pt) Anticorpo anti-clec12a ou fragmento de ligação ao antígeno, método de tratamento de um câncer, composição farmacêutica, sequência de ácidos nucleicos, vetor, célula, e, método de tratamento de câncer
MX2023008597A (es) Metodos de tratamiento del cancer usando anticuerpos anti-tigit en combinacion con anticuerpos anti-pd1.
MX2022011801A (es) Anticuerpos monoclonales contra acidos nucleicos modificados quimicamente y usos de los mismos.
PH12023552704A1 (en) Novel multispecific antibodies
GEAP202416379A (en) Multispecific Binding Moieties Comprising Novel Pd-1 Binding Domains
WO2024216007A3 (en) Pd-1/tigit binding proteins for cancer treatment
DK1079856T3 (da) Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme